Core Viewpoint - The company reported strong financial performance for the first half of 2025, with revenue and net profit showing significant year-on-year growth, indicating a robust business trajectory and potential for future expansion [1][2]. Financial Performance - In H1 2025, the company achieved revenue of 822 million yuan, representing a year-on-year increase of 12.50% [1][2]. - The net profit attributable to shareholders was 235 million yuan, up 24.55% year-on-year, while the net profit excluding non-recurring items reached 226 million yuan, reflecting a growth of 20.94% [1][2]. - The gross margin and net margin for H1 2025 were 60.11% and 28.58%, respectively, showing improvements of 309 basis points and 277 basis points compared to the previous year [2]. Business Segments - The raw material pharmaceutical business exhibited rapid growth, with revenue in H1 2025 reaching 700 million yuan, a year-on-year increase of 24.68% [3]. - Key product categories such as cardiovascular, respiratory, women's health, nervous system, and anti-infection raw materials showed steady growth, while new products in the peptide and oligonucleotide segments contributed to sales growth [3]. Future Outlook - The company anticipates continued growth in key products like Dydrogesterone, Abiraterone, and others, alongside new product launches expected to drive revenue increases over the next 3-5 years [2][4]. - The company is focusing on expanding hospital coverage for Dydrogesterone, with 1,754 new hospital additions in H1 2025, leading to a sales revenue of approximately 95.7 million yuan, a 3.5% increase year-on-year [2]. Investment Recommendations - The company is expected to maintain high growth rates in the coming years due to the ongoing expansion of existing products and the commercialization of potential blockbuster products [4]. - Revenue forecasts for 2025-2027 have been adjusted to 1.777 billion, 2.154 billion, and 2.591 billion yuan, respectively, with corresponding EPS estimates revised to 1.15, 1.47, and 1.84 yuan [4].

Core Viewpoint - The recent financial report of Aorite (605116) shows strong growth in revenue and net profit, indicating improved profitability and operational efficiency [1][2]. Financial Performance - As of the end of the reporting period, the company's total revenue reached 822 million yuan, a year-on-year increase of 12.5%, while the net profit attributable to shareholders was 235 million yuan, up 24.55% year-on-year [1]. - In the second quarter, total revenue was 420 million yuan, reflecting a 6.31% year-on-year growth, and the net profit attributable to shareholders was 115 million yuan, an increase of 8.53% year-on-year [1]. - The gross margin improved by 5.42% year-on-year to 60.11%, and the net margin increased by 10.72% to 28.58% [1]. - Total selling, administrative, and financial expenses amounted to 159 million yuan, accounting for 19.38% of revenue, which is a 9.01% increase year-on-year [1]. - Earnings per share (EPS) reached 0.58 yuan, a 26.09% increase year-on-year, and operating cash flow per share was 0.53 yuan, up 28.71% year-on-year [1]. Business Evaluation - The company's return on invested capital (ROIC) for the previous year was 13.26%, indicating strong capital returns [2]. - The net profit margin for the previous year was 24.04%, suggesting high added value in its products or services [2]. - Historical data shows that the median ROIC since the company went public is 13.26%, with the lowest ROIC recorded in 2017 at 8.99% [2]. Debt and Receivables - The company has a debt situation to monitor, with interest-bearing asset-liability ratio reaching 24.8% [3]. - The accounts receivable to profit ratio has reached 100.19%, indicating potential concerns regarding cash flow [3]. Fund Holdings - The largest fund holding Aorite is the Huaxia Zhuoxin One-Year Open-End Bond Initiated Fund, which holds 700,000 shares and has a total scale of 6.019 billion yuan [4]. - The fund's latest net value is 1.1317 as of August 29, with a slight decrease of 0.01% from the previous trading day, but it has increased by 6.35% over the past year [4].

Core Viewpoint - Aurisco Pharmaceutical Co., Ltd. reported a significant increase in revenue and net profit for the first half of 2025, driven by market expansion and new product launches [2][3][12]. Company Overview and Financial Indicators - The company specializes in the research, production, and sales of complex active pharmaceutical ingredients (APIs), intermediates, and formulations, focusing on high-quality products with significant entry barriers [4][10]. - For the first half of 2025, the company achieved a revenue of approximately 822 million RMB, a 12.5% increase from the previous year, and a net profit attributable to shareholders of approximately 235 million RMB, reflecting a 24.55% growth [3][12]. - The company’s total assets reached approximately 3.90 billion RMB, with a net asset value of approximately 2.43 billion RMB, marking a 4.19% increase from the end of the previous year [3][12]. Business Model and Operations - The company operates a customer-oriented business model, leveraging its technological platform to develop and produce market-potential products, while also engaging in the trade of pharmaceutical intermediates and APIs [4][6]. - The production process adheres strictly to domestic and international GMP standards, ensuring product safety and quality [5][14]. - The sales strategy primarily focuses on exporting APIs, with a stable customer base built through long-term partnerships with major international pharmaceutical companies [5][6]. Industry Context - The global pharmaceutical market is projected to grow from approximately 1.6 trillion USD in 2023 to about 2.2 trillion USD by 2028, driven by increased drug usage, new product launches, and the rise of biosimilars [8][9]. - The Chinese pharmaceutical manufacturing industry is experiencing slight fluctuations in revenue and profit due to policies like volume-based procurement and medical insurance cost control [10][11]. - The raw material drug sector is becoming increasingly important, with China emerging as a major producer and exporter of APIs, supported by government policies promoting high-quality development [11][12]. Competitive Advantages - The company has established a comprehensive quality management system compliant with international standards, enhancing its competitive edge in the market [15][16]. - A strong focus on R&D has led to the development of a diverse product line across various therapeutic areas, including cardiovascular, respiratory, and oncology [14][15]. - The company maintains robust relationships with major global pharmaceutical firms, ensuring a stable revenue stream and market presence [15].

第三节 重要事项 公司应当根据重要性原则，说明报告期内公司经营情况的重大变化，以及报告期内发生的对公司 经营情况有重大影响和预计未来会有重大影响的事项 □适用 √不适用 □适用 √不适用 □适用 √不适用 □适用 √不适用 | 奥锐特药业股份有限公司2025 | | 年半年度报告摘要 | | | --- | --- | --- | --- | | 公司代码：605116 | | 公司简称：奥锐特 | | | 债券代码：111021 | | 债券简称：奥锐转债 | | | 奥锐特药业股份有限公司 | | | | | 奥锐特药业股份有限公司2025 | | 年半年度报告摘要 | | | 第一节 | 重要提示 | | | | 展规划，投资者应当到 | www.sse.com.cn | 网站仔细阅读半年度报告全文。 | | | 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 | | | | | 不适用 | | | | | 第二节 | 公司基本情况 | | | | 公司股票简况 | | | | | 股票种类 | 股票上市交易所 | 股票简称 | 股票代码 变更前股票简 | | 称 | | | ...

Group 1 - The third meeting of the board of directors of Aorite Pharmaceutical Co., Ltd. was held on August 27, 2025, with all 9 directors present, and the resolutions made were deemed legal and effective [1] - The board approved the use of up to RMB 100 million of temporarily idle raised funds for cash management, investing in safe and liquid financial products with a maturity of no more than 12 months [2][3] - The company plans to hold its first extraordinary general meeting of 2025 on September 26, 2025, to discuss various proposals, including changes to governance structures [7] Group 2 - The board's resolutions included the approval of a special report on the actual use of raised funds, which will be disclosed on August 29, 2025 [2] - The company is set to revise its governance documents in accordance with the latest regulatory requirements from the China Securities Regulatory Commission and the Shanghai Stock Exchange [6] - The board's decisions regarding the cancellation of the supervisory board and changes to the company's registered capital will also be submitted for shareholder approval [4][5]

General Principles - The company establishes a management system for the departure of directors and senior management to ensure stability and continuity in governance and protect the legal rights of the company and its shareholders [1] - The system applies to various departure scenarios including term expiration, resignation, dismissal, retirement, and other reasons [2] Departure Procedures - Directors and senior management can resign before their term ends by submitting a written resignation report, which becomes effective upon receipt by the board [2] - The company must disclose the resignation details within two trading days, including reasons and impacts [2][3] Responsibilities and Obligations - Departing directors and senior management must complete handover procedures within five working days, including transferring unfinished matters and relevant documents [4] - Confidentiality obligations regarding trade secrets and insider information remain effective after departure [5] Shareholding Management - Departing directors and senior management are prohibited from transferring their shares within six months post-departure [6] - Any commitments regarding shareholding changes must be strictly adhered to [6] Accountability Mechanism - The company reserves the right to seek compensation from departing directors and senior management for any losses caused by violations of laws or regulations [7][8]

Core Points - The article outlines the selection and appointment process for accounting firms at Aorite Pharmaceutical Co., Ltd, emphasizing the importance of maintaining shareholder interests and ensuring the quality of financial information [1][2] - The selection process requires the approval of the audit committee, the board of directors, and ultimately the shareholders [2][3] - The article specifies the qualifications and quality requirements for accounting firms, including relevant licenses, experience with large public companies, and a good reputation [1][2][3] Selection Process - The audit committee proposes the appointment of accounting firms, which must be approved by a majority of its members [2] - The audit committee is responsible for overseeing the selection process, including developing policies, evaluating proposals, and submitting recommendations to the board [2][3] - Various methods for selecting accounting firms are outlined, including competitive negotiation, public bidding, and invitation to tender [3][4] Evaluation Criteria - The evaluation of accounting firms must consider multiple factors, with a minimum weight of 40% on quality management and a maximum of 15% on audit fees [4][5] - The company must document and retain evaluation opinions from the selection process [4][5] - The selection process must be transparent, with relevant information published on the company's official channels [3][4] Appointment and Renewal - The appointed accounting firm must fulfill its obligations as per the audit agreement and cannot subcontract the work [5][6] - The audit committee must evaluate the performance of the accounting firm before renewing its appointment for the next year [5][6] - Adjustments to audit fees can be made based on various factors, and significant decreases must be disclosed [6][7] Circumstances for Replacement - The company must replace the accounting firm under specific conditions, such as significant quality issues or failure to meet deadlines [7][8] - The board must notify shareholders and allow the previous firm to present its case if a replacement is proposed [7][8] Oversight and Compliance - The audit committee is tasked with monitoring the compliance of the appointed accounting firm with legal and regulatory requirements [8][9] - Any violations by the selected accounting firm that result in severe consequences must be reported to the board [8][9] - Documentation related to the selection and evaluation process must be retained for at least ten years [8][9]

第一章 总 则 第一条 为加强奥锐特药业股份有限公司（以下简称"公司"）内部审计工作， 提高内部审计工作质量，保护投资者合法权益，依据《上海证券交易所上市公司 自律监管指引第 1 号——规范运作》《中华人民共和国审计法》等法律、法规及 中国证监会的相关规定，结合本公司内部审计工作的实际情况，制定本制度。 第二条 本制度适用于公司全资、控股子公司以及具有重大影响的参股公司所 有业务环节的内部审计工作。 第三条 本制度所称内部审计，是指由公司内部审计部门依据国家有关法律法 规和本制度的规定，开展的审计评价活动。 奥锐特药业股份有限公司 内部审计制度 第二章 内部审计组织机构及工作职责 第四条 公司设立内部审计部门，对公司业务活动、风险管理、内部控制、财 务信息等事项进行监督检查。内部审计部门对董事会负责，向董事会审计委员会 报告工作。公司董事会审计委员会负责指导和监督内部审计部门工作，内部审计 部门发现公司重大问题或线索，应当立即向董事会审计委员会直接报告。 第五条 内部审计部门应当保持独立性，不得置于财务部门的领导之下，或者 与财务部门合署办公。 第六条 从事内部审计的工作人员应具备必要的审计业务知识。 内部审 ...

奥锐特药业股份有限公司 突发危机事件应急管理制度 第一章 总 则 第一条 为了加强奥锐特药业股份有限公司（以下简称"公司"）突发危机事件的应 急管理，建立快速反应和应急处置机制，最大程度降低突发危机事件造成的影响和损失， 维护公司正常的生产经营秩序，保护广大投资者的合法利益，根据《中华人民共和国公 司法》、《中华人民共和国证券法》、《中华人民共和国突发事件应对法》、《上海证券交 易所股票上市规则》及《奥锐特药业股份有限公司章程》等有关规定，结合公司实际情 况，制定本制度。 第二条 本制度适用于公司及各分、子公司。 第三条 本制度所称突发危机事件是指突然发生的、有别于日常经营的、已经或者 可能会对公司的经营、财务状况、资产安全以及对公司的声誉、股票及其衍生品价格产 生严重影响，需要采取应急处置措施予以应对的偶发性事件。 第四条 公司应对突发危机事件工作实行以预防为主、预防与应急处置相结合的原 则。 第五条 公司应当至少关注下列风险： （一）突发危机事件的发生可能影响公司战略的执行与实现。 （二）突发危机事件可能影响公司正常经营活动。 （三）突发危机事件可能造成人员、财产和信誉损失，影响公司社会形象。 第二章 事 ...

第一章 总则 第一条 为规范奥锐特药业股份有限公司（以下简称"公司"或"本公司"）信息 披露暂缓与豁免行为，确保本公司及相关信息披露义务人依法合规履行信息披露义务， 保护投资者合法权益，根据《中华人民共和国证券法》 《上海证券交易所股票上市规则》 （以下简称《股票上市规则》）、《上市公司信息披露管理办法》及《奥锐特药业股份有 限公司章程》（以下简称《公司章程》），特制定本制度。 第二条 公司按照《股票上市规则》及上海证券交易所其他相关业务规则的规定， 办理信息披露暂缓、豁免业务的，适用本制度。 第三条 公司应当披露的信息存在《股票上市规则》及上海证券交易所其他相关规 则中规定的暂缓、豁免情形的，由公司自行审慎判断，可依照本制度经公司内部审批后 暂缓、豁免披露，并接受上海证券交易所对有关信息披露暂缓、豁免事项的事后监管。 第二章 暂缓、豁免披露信息的范围 第四条 公司及相关信息披露义务人有确实充分的证据证明拟披露的信息涉及国家 秘密或者其他因披露可能导致违反国家保密规定、管理要求的事项（以下统称国家秘密）， 依法豁免披露。 奥锐特药业股份有限公司 信息披露暂缓与豁免管理制度 公司及相关信息披露义务人应当切实履行 ...